England seeks views on including men in HPV vaccine programme
This article was originally published in Scrip
Executive Summary
Just as the UK's NHS prepares to switch from GlaxoSmithKline's human papillomavirus vaccine Cervarix to Sanofi Pasteur MSD's Gardasil, England's Joint Committee on Vaccination and Immunisation has put out a call for evidence on whether it should amend its HPV immunisation programme to include men. It will be considering how some men might benefit from vaccination and the potential impact of higher valency vaccines.